Maria R Baer

RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures.

Guido Marcucci, Jessica Kohlschmidt, Heiko Becker, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Tyrosine Kinase Inhibitor Imatinib Mesylate Enhances the Efficacy of Photodynamic Therapy by Inhibiting ABCG2

Janet Morgan, Paula Pera, Xiang Zheng, 2007, Clinical Cancer Research.

Epigenetics meets genetics in acute myeloid leukemia: clinical impact of a novel seven-gene score.

Pearlly Yan, Ralf Bundschuh, David Frankhouser, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Signal transducer and activator of transcription proteins in leukemias.

Heinz Baumann, Meir Wetzler, H. Baumann, 2003, Blood.

Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461.

Yi Ning, Kellie J Archer, C. Bloomfield, 2006, Blood.

Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance.

D. Ross, M. Baer, Douglas D Ross, 2012, Biochemical pharmacology.

Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

Guido Marcucci, Heiko Becker, Sebastian Schwind, 2010, Blood.

Simvastatin–Fluconazole Causing Rhabdomyolysis

Aasma Shaukat, Meir Wetzler, G. Vladutiu, 2003, The Annals of pharmacotherapy.

Translocation (4;11)(p12;q23) with rearrangement of FRYL and MLL in therapy-related acute myeloid leukemia.

N. Nowak, J. Conroy, S. Sait, 2007, Cancer genetics and cytogenetics.